Navigation Links
BUSM study identifies receptor's role in regulating obesity, type 2 diabetes
Date:7/26/2012

(Boston) A recent study led by Boston University School of Medicine (BUSM) demonstrates that the A2b-type adenosine receptor, A2bAR, plays a significant role in the regulation of high fat, high cholesterol diet-induced symptoms of type 2 diabetes. The findings, which are published online in PLoS ONE, also identify A2bAR as a potential target for the treatment of type 2 diabetes.

Katya Ravid, DSc/PhD, professor of medicine and biochemistry and director of the Evans Center for Interdisciplinary Biomedical Research at BUSM, led this study. Colleagues from Ravid's lab who collaborated on this research include Hillary Johnston-Cox, BSc (MD/PhD, 2014) and Milka Koupenova-Zamor, PhD. Noyan Gokce, MD, associate professor of medicine at BUSM, and Melissa Farb, PhD, a postdoctoral fellow at BUSM, also collaborated on the study.

Diets that are high in fat and cholesterol induce changes in how the body regulates blood glucose levels. Exercise induces an increased production adenosine, a metabolite produced naturally by cells. A2bAR, a naturally occurring protein receptor found in the cell membrane, is activated by adenosine. This receptor is known to play an important role in regulating inflammation, which is associated with type 2 diabetes and obesity.

To examine the association of A2bAR activation with a diet high in fat and cholesterol, the researchers used an experimental model that lacked A2bAR and compared the results with a control group. When the experimental model group was given a diet high in fat and cholesterol, there was an increase in the development of obesity and signs of type 2 diabetes. The signs demonstrated in the study included elevated blood glucose levels and increased in insulin levels. When the control group was given the same diet, however, the levels of A2bAR increased, resulting in decreased insulin and glucose levels and obesity.

A novel link also was identified between the expression of A2bAR, insulin receptor substrate 2 (IRS-2) and insulin signaling. The results showed that the level of IRS-2, a protein that has previously been shown to mediate the effect of insulin, was impaired in tissues of the experimental model lacking A2bAR, causing higher concentrations of blood glucose. When A2bAR was activated in the control group using a pharmacologic agent with a diet high in fat and cholesterol, the level of IRS-2 was upregulated, lowering blood glucose.

"The pharmacologic activation of A2bAR demonstrated its newly identified role in signaling down to regulate the levels of IRS-2, which then improved the signs of high fat diet-induced type 2 diabetes," said Ravid.

The prevalence of type 2 diabetes and obesity continues to increase in developed countries and both factors are known to contribute to the development of cardiovascular disease. According to the World Health Organization, 346 million people worldwide have diabetes and 90 percent of those people have type 2 diabetes.

To correlate these results in humans, the researchers then examined fat tissue samples from obese individuals. The results showed that A2bAR expression is high in fat from obese individuals, marked by inflammation, compared to lean ones, and is strongly correlated with IRS-2 expression.

"Our study suggests the important role of A2bAR in maintaining the level of IRS-2, a regulator of glucose and insulin homeostasis," added Ravid.


'/>"/>
Contact: Jenny Eriksen Leary
jenny.eriksen@bmc.org
617-638-6841
Boston University Medical Center
Source:Eurekalert

Related biology news :

1. Study associates excess maternal iodine supplementation with congenital hypothyroidism in newborns
2. New study associates excess maternal iodine supplementation with congenital hypothyroidism
3. Its a bird, not a plane: York U study finds migrating songbirds depart on time
4. Alpine Fault study shows new evidence for regular magnitude 8 earthquakes
5. Researchers study knee stress at tissue, cellular levels
6. DataONE answers the call for new tools to study the Earth in this era of Big Data science
7. Study shows economic feasibility for capturing carbon dioxide directly from the air
8. New study: Raisins as effective as sports chews for fueling workouts
9. PSU study finds caffeinated coastal waters
10. New study announced that will use genetics to test for Alzheimers risk
11. Study points to causes of high dolphin deaths in Gulf of Mexico
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/7/2016)... Jan. 7, 2016 This BCC Research report ... biometric technologies and devices, identifying newer markets and exploring ... types of biometric devices. Includes forecast from 2015 to ... newer markets and explore the expansion of the present ... each type of biometric technology, determine its current market ...
(Date:1/7/2016)... -- A United States District Court in Illinois ... to interpret a biometric privacy statute in a decision ... photo website Shutterfly brought by the law firm Carey Rodriguez ... SHUTTERFLY, INC.; and THISLIFE, INC ( N.D. Ill ., ... Illinois Biometric Privacy Act by collecting and scanning face ...
(Date:1/6/2016)... Calif. , Jan. 6, 2016 ... biometrics market, Frost & Sullivan recognizes MorphoTrak, LLC, ... 2015 North American Frost & Sullivan Company of ... contactless fingerprint scanning technology, Morpho Wave™ , has ... in the fingerprint biometrics market. Morpho Wave ...
Breaking Biology News(10 mins):
(Date:2/8/2016)... 8, 2016 --> ... an innovation-driven oncology company developing next generation cancer ... today announced that chairman emeritus of Tata Sons ... the company as part of the first close ... investors Navam Capital and Aarin Capital. ...
(Date:2/8/2016)... Md. , Feb. 8, 2016  BioElectronics ... consumer medical devices, announced today that it is ... administrative proceedings from the Securities and Exchange Commission ... Richard Staelin , Chairman of the Board of ... Professor of Business Administration at The Fuqua School ...
(Date:2/8/2016)... ... February 08, 2016 , ... Franz Inc. ... Graph Database technology, today announced the availability of AllegroGraph 6, the leading Semantic ... Cloudera Certified Technology Program (CCPT). AllegroGraph is the first Semantic Graph ...
(Date:2/8/2016)... Pharmacy, Inc. (NYSE: DPLO) announced today that its new website has gone live. On Thursday, Feb. ... Visit the new site: www.diplomat.is ... ... ... "The goal was to reimagine the website and create a ...
Breaking Biology Technology: